Publications

November 2016
Supplement

Alnylam Pharmaceuticals: Building Value from the IP Estate (B)

By: Vicki Sato, Willy Shih and Matt Higgins

The leader of a pioneering biotech company in the siRNA space weighs his options for scaling production capacity in advance of an anticipated commercial launch. Operational complexity and relative merits of in-house manufacturing versus a contractor model are... View Details

Keywords: Pharmaceutical Companies; Pharmaceutical Industry; Biotech; Biotechnology; Operational Complexity; Strategy; Manufacturing; Production; Strategic Planning; Intellectual Property; Biotechnology Industry; United States

October 2012
Supplement

Aqua Bounty Courseware

By: Lucy White and Steve Burn-Murdoch

Valuation of a pre-revenue biotech company at IPO using probability trees and real option techniques. Company is based in Massachusetts and lists in London on AIM. Products are genetically-modified fast-growing salmon for fish farmers and disease-prevention drugs and... View Details

Keywords: IPO; Valuation; Real Options; Decision Tree; Biotech; Genetically Modified; Salmon; Entrepreneurship; Finance; Agriculture and Agribusiness Industry; Biotechnology Industry; North and Central America; Europe; South America

November 2016
Case

QuintilesIMS: Biosimilar Marketing in England

By: John A. Quelch and Emily C. Boudreau

QuintilesIMS was a leading healthcare consulting firm best known for its data and information offerings as well as its market research and management consulting services for life science companies. By 2015, the company was expanding beyond the biopharmaceutical... View Details

Keywords: Health; Pharmaceutical Industry; Biotech; Marketing; Health Care and Treatment; Biotechnology Industry; England

September 2012 (Revised January 2014)
Case

Aqua Bounty

By: Lucy White and Stephen Burn-Murdoch

Valuation of a pre-revenue biotech company at IPO using probability trees and real option techniques. Company is based in Massachusetts and lists in London on AIM. Products are genetically-modified fast-growing salmon for fish farmers and disease-prevention drugs and... View Details

Keywords: IPO; Valuation; Real Options; Decision Tree; Biotech; Genetically Modified; Salmon; Entrepreneurship; Finance; Agriculture and Agribusiness Industry; Biotechnology Industry; North and Central America; Europe; South America

January 2021
Case

Takeda Pharmaceutical Company Limited (A)

By: David J. Collis, Nobuo Sato and Akiko Kanno

This case follows Christophe Weber, President and CEO of Takeda Pharmaceutical Company Limited, a leading pharmaceutical company headquartered in Tokyo, Japan, as Takeda considers acquiring Shire Plc, a biotech company based in Ireland. The acquisition would turn... View Details

Keywords: Pharmaceutical Companies; Pharmaceuticals; Biotech; Biotechnology; M＆A; Mergers ＆ Acquisitions; R＆D; Talent Management; Mergers and Acquisitions; Globalization; Management; Global Strategy; Talent and Talent Management; Pharmaceutical Industry; Biotechnology Industry; Japan; Asia

2009
Case

Innovamedica: Innovation in an Emerging Market

By: Roberto Charvel, Fernando Fabre and T. Putimahtama

Innovamedica was a medical start up with several state of the art devices such as a silicon substitute heart and other inventions. However, the founding scientist was struggling in attracting talent and fundraising and that had an impact on growth. View Details

Keywords: Biotech; Entrepreneurial Finance; Entrepreneurship; Start-up; Emergent Countries; Business Startups; Talent and Talent Management; Design; Corporate Entrepreneurship; Private Equity; Health Testing and Trials; Innovation and Invention; Managerial Roles; Biotechnology Industry; Latin America; North and Central America

September 2020 (Revised January 2021)
Case

Catalys Pacific

By: Joshua Lev Krieger

In 2019, BT Slingsby founds Catalys Pacific, the first biotech “venture creation” fund in Tokyo. After convincing some of the biggest Japanese pharmaceutical firms to invest, BT hopes the fund can make a big splash and transform biotechnology innovation in Japan. After... View Details

Keywords: Pharmaceutical Companies; Biotech; Health Care; Entrepreneur; Innovation; International Business; Entrepreneurial Finance; Entrepreneurship; Finance; Innovation Strategy; Venture Capital; Strategy; Cross-Cultural and Cross-Border Issues; Pharmaceutical Industry; Biotechnology Industry; Tokyo

November 2016 (Revised December 2016)
Supplement

Anthony Starks at InSiL Therapeutics (B)

By: Vicki Sato and Gary Pisano

This case accompanies the (A) case from Anthony Starks's perspective. View Details

Keywords: Biotech; Management Challenges; R＆D; R＆D Project Management; Management; Biotechnology Industry; California

January 2021
Supplement

Takeda Pharmaceutical Company Limited (B)

By: David J. Collis, Nobuo Sato and Akiko Kanno

This case is a follow up to HBS Case No. 721-373, Takeda Pharmaceutical Company Limited (A). Following the events of the previous case, Takeda reached an agreement to acquire Ireland-based Shire Plc. The case follows some of the achievements and challenges Takeda and... View Details

Keywords: Pharmaceutical Companies; Pharmaceuticals; M＆A; Mergers ＆ Acquisitions; Biotech; Biotechnology; R＆D; Talent Management; Mergers and Acquisitions; Globalization; Global Strategy; Talent and Talent Management; Strategy; Biotechnology Industry; Pharmaceutical Industry; Japan; Asia

January 2014
Supplement

Fred Khosravi and AccessClosure (C)

By: Richard Hamermesh and Lauren Barley

On September 11, 2013, the three-judge panel of the U.S. Court of Appeals for the Federal Circuit denied St. Jude's request to rehear an appeal on the "double patenting" ruling for the '439 patent. Further, it removed the injunction threat that was hanging over the... View Details

Keywords: Medical Devices; Vascular Closure Device; Patent Litigation; Patenting; Biomedical Research; Biotechnology; Biotech; Technological Innovation; Patents; Health Care and Treatment; Biotechnology Industry; United States

October 2013 (Revised January 2014)
Supplement

Fred Khosravi and AccessClosure (B)

By: Richard G. Hamermesh and Lauren Barley

It was January 2013, and Fred Khosravi, chairman of the board of AccessClosure Inc., wondered what the new year had in store for him and AccessClosure, the company he founded in late 2002. Khosravi was cautiously optimistic—the Mountain View, California-based medical... View Details

Keywords: Medical Devices; Vascular Closure Device; Patent Litigation; Patenting; Biomedical Research; Biotechnology; Biotech; Technological Innovation; Patents; Health Care and Treatment; Biotechnology Industry; United States; California